OOIR: Observatory of International Research

Papers

(The H4-Index of Experimental Hematology & Oncology is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	200
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	168
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	164
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	142
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity	137
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	111
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	105
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	84
A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms	80
MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting	79
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	77
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	75
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	74
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	73
Inhibition of EYA family tyrosine phosphatase activity reveals a therapeutic vulnerability and enhances Menin and DOT1L inhibitor efficacy in KMT2A-rearranged leukemia	70
Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy	68
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	67
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	63
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	62
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors	60
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	59
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	57
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	54
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	54
HIV associated lymphoma: latest updates from 2023 ASH annual meeting	52

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways	51
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	48
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	48
Enhanced cellular therapy: revolutionizing adoptive cellular therapy	46
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies	45
Role of m6A writers, erasers and readers in cancer	44
Breast cancer heterogeneity and its implication in personalized precision therapy	44
Three-dimensional chromatin landscapes in MLLr AML	43
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia	42
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells	42
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma	41
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting	41
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways	41
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma	41
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study	40